How the H3.3 G34R mutation changes DNA repair and immune response in pediatric high-grade glioma
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.
This work looks at how a specific tumor mutation (H3.3 G34R) changes DNA repair, the tumor immune environment, and resistance to treatment in pediatric high-grade glioma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11247515 on NIH RePORTER |
What this research studies
Researchers create immune-competent mouse models that carry the same H3.3 G34R mutation found in a subtype of pediatric high-grade glioma and compare them to tumors without the mutation. They use gene sequencing and chromatin-accessibility methods (like ATAC-seq) to see how DNA damage response pathways and immune signals differ. The team studies how those changes may make tumors resist radiation, chemotherapy, or immune attack. Results will be used to point toward molecular targets or strategies to overcome resistance in this tumor subtype.
Who could benefit from this research
Good fit: Ideal participants would be children or adolescents with hemispheric high-grade glioma that carry the H3.3 G34R mutation, or families willing to contribute tumor samples for research.
Not a fit: Patients whose tumors do not carry the H3.3 G34R mutation or who have unrelated adult brain cancers are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this work may identify new treatment targets or ways to boost anti-tumor immunity to improve outcomes for children with H3.3 G34R high-grade glioma.
How similar studies have performed: Similar genetically engineered mouse models and sequencing approaches have revealed actionable biology in brain tumors, but the H3.3 G34R mutation’s effects on DNA repair and immunity are relatively new and less explored.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Castro, Maria G — University of Michigan at Ann Arbor
- Study coordinator: Castro, Maria G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.